Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis

Abstract

Background Malignant tumor is one of the most serious diseases endangering human health. Circular RNAs play an important role in the tumorigenesis and progression of various malignant tumors. Although various studies have investigated the biological function of circular RNA circSMARCA5 in malignant tumors, the prognostic value of circSMARCA5 in malignant tumor patients has not been systematically analyzed. Methods Relevant studies were obtained from the PubMed and Web of Science database. The quality of the enrolled studies was evaluated using the Newcastle-Ottawa Scale quality assessment system. Survival features and clinicopathological features were assessed using pooled hazard ratios and odds ratios with 95% confidence intervals, respectively. Results Overall, 7 relevant publications were enrolled in the meta-analysis. CircSMARCA5 expression was significantly correlated with better OS (HR = 0.51, 95%CI 0.41–0.65) or DFS/RFS/PFS (HR = 0.56, 95%CI 0.43–0.73) in malignant tumors. In the pooled analyses of clinicopathological characteristics, malignant tumors with higher circSMARCA5 were better differentiated (OR = 0.41, 95%CI 0.19–0.88). CircSMARCA5 expression was correlated with less advanced TNM stage (OR = 0.33, 95%CI 0.19–0.55). Moreover, malignant tumors with higher circSMARCA5 expression have less advanced lymph node metastasis (OR = 0.26, 95%CI 0.08–0.79). Conclusion These results indicated that circSMARCA5 was a promising biomarker in malignant tumors, which may potentially facilitate clinical decisions in the future.

CircSMARCA5 functions as a potential biomarker for clinicopathology and therapy in solid tumors: A systematic review and meta‐analysis

“…Up to now, there are several meta‐analyses about circRNAs and one meta‐analysis about circSMARCA5. Chao et al 40 enrolled seven publications to illustrate that circSMARCA5 could be a favorable biomarker in carcinomas, due to its correlation with better OS, disease‐free survival, RFS, and progression‐free survival. Our study enrolled eight studies to analyze the association among clinicopathological characteristics and therapeutic targets with circSMARAC5 expression, which was different from previous studies and exerted a supplementary function.…”

Circular RNA MYLK as a prognostic biomarker in patients with cancers: A systematic review and meta‐analysis

“… 31 Chao et al discovered that circSMARCA5 is a promising biomarker in human cancers, which may assist in the management of cancer patients in the future. 32 Exploring the potential of circRNAs as biomarkers can provide valuable information for clinical decision‐making. However, the effect of circMYLK on the prognosis of cancers has not been systematically analyzed.…”

“…Furthermore, Lin et al proposed that high circPVT1 expression is correlated with poor prognosis in malignancies 31 . Chao et al discovered that circSMARCA5 is a promising biomarker in human cancers, which may assist in the management of cancer patients in the future 32 . Exploring the potential of circRNAs as biomarkers can provide valuable information for clinical decision‐making.…”

Hsa_circ_0056686, derived from cancer-associated fibroblasts, promotes cell proliferation and suppresses apoptosis in uterine leiomyoma through inhibiting endoplasmic reticulum stress

“…Accumulated evidence showed that circRNAs are abnormally expressed in many cancers including ULM, which are key players in cancer initiation, development and progression. Specially, in the pathological processes of tumor cells, circRNAs participate in cell proliferation, apoptosis, invasion and migration [ 8 , 9 ]. For example, hsa_circ_0043265 level is significantly upregulated in non-small lung cancer cells, and can act as an oncogene to restrain proliferation, migration, invasion and EMT process in non-small cell lung cancer [ 10 ].…”